Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 4—April 2018

Reemergence of Intravenous Drug Use as Risk Factor for Candidemia, Massachusetts, USA

Nongnooch Poowanawittayakom, Anamika Dutta, Shannon Stock, Sunkaru Touray, Richard T. Ellison, and Stuart M. LevitzComments to Author 
Author affiliations: University of Massachusetts Medical School, Worcester, Massachusetts, USA (N. Poowanawittayakom, S. Touray, R.T. Ellison III, S.M. Levitz); College of the Holy Cross, Worcester (A. Dutta, S. Stock)

Main Article

Table 5

Outcomes of patients with candidemia, Massachusetts, USA, 2010–2017*

Outcome IVDU, n = 24 Non-IVDU, n = 174 p value
Death, no. (%) patients 5 (20.8) 60 (34.5) 0.247
Median length of hospital stay (IQR), d 11 (17.5) 19 (27.5) 0.059

*IQR, interquartile range; IVDU, intravenous drug use.

Main Article

Page created: March 16, 2018
Page updated: March 16, 2018
Page reviewed: March 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.